A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
A phase 1/2 trial of Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Cho Pharma Inc., active and no longer recruiting.
Overview
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05950165 by Cho Pharma Inc., with 37 participants planned, started 2020-01-15 and due to reach its primary completion in 2026-12-23. Interventions recorded: CHO-H01, CHO-H01 at RP2D, Lenalidomide. Conditions listed: Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide to Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase
Phase 1/2
Sponsor
Cho Pharma Inc.
Registry
Enrolled
37
Similar pages
not linked directly; found by shared links- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialStudy of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Shares Lenalidomide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- TrialA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat
- TrialSafety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- TrialA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom